IndiaTuberculosis profile
Population  2016 1 324 million
Estimates of TB burden*, 2016 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 420 (320–530) 32 (24–40)
Mortality (HIV+TB only) 12 (6.6–19) 0.92 (0.5–1.5)
Incidence  (includes HIV+TB) 2 790 (1 440–4 570) 211 (109–345)
Incidence (HIV+TB only) 87 (56–125) 6.6 (4.3–9.4)
Incidence (MDR/RR-TB)** 147 (95–199) 11 (7.2–15)
Estimated TB incidence by age and sex (thousands)*, 2016
  0-14 years > 14 years Total
Females 107 (47–167) 897 (391–1 400) 1 000 (437–1 570)
Males 120 (52–188) 1 660 (725–2 600) 1 780 (778–2 790)
Total 227 (99–355) 2 560 (1 120–4 010) 2 790 (1 440–4 570)
TB case notifications, 2016  
Total cases notified 1 936 158
Total new and relapse 1 763 876
          - % tested with rapid diagnostics at time of diagnosis 17%
          - % with known HIV status 72%
          - % pulmonary 84%
          - % bacteriologically confirmed among pulmonary 63%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2016 63% (39–120)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2016 0.17 (0.09–0.27)
TB/HIV care in new and relapse TB patients, 2016 Number (%)
Patients with known HIV-status who are HIV-positive 39 815 3%
          - on antiretroviral therapy 39 123 98%
Drug-resistant TB care, 2016 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  84 000
(72 000–95 000)
Estimated % of TB cases with MDR/RR-TB 2.8% (2–3.5) 12% (10–13)  
% notified tested for rifampicin resistance 20% 67% 580 438
MDR/RR-TB cases tested for resistance to second-line drugs   22 492
Laboratory-confirmed cases MDR/RR-TB: 37 258, XDR-TB: 2 464
Patients started on treatment **** MDR/RR-TB: 32 914, XDR-TB: 2 475
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2015 72% 1 656 233
Previously treated cases, excluding relapse, registered in 2015 66% 69 823
HIV-positive TB cases registered in 2015 78% 44 191
MDR/RR-TB cases started on second-line treatment in 2014 46% 22 524
XDR-TB cases started on second-line treatment in 2014 29% 1 262
TB preventive treatment, 2016  
% of HIV-positive people (newly enrolled in care) on preventive treatment 5%
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
1.9% (1.7–2)
TB financing, 2017  
National TB budget (US$ millions) 525
Funding source: 74% domestic, 26% international, 0% unfunded
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2016
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2017-12-17 Data: www.who.int/tb/data